

Diabetic Foot Ulcer Treatment Market will experience significant changes during the forecast period of 2024–2034

Diabetic Foot Ulcer Treatment Market

DELHI, DELHI, INDIA, July 8, 2024 /EINPresswire.com/ -- DelveInsight's "Diabetic Foot Ulcer Market Insights, Epidemiology and Market Forecast – 2034" report delivers an in-depth understanding of Diabetic Foot Ulcer (DFU), historical and forecasted epidemiology as well as the Diabetic Foot Ulcer (DFU) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.



Diabetic foot ulcers Drugs Market

Discover the latest insights on Diabetic Foot Ulcer Market Forecast. Stay ahead with DelveInsight's comprehensive analysis! @ [Diabetic Foot Ulcer Drugs Market](#)

Key Takeaways from the Diabetic Foot Ulcer Market Report

- June 2024:- Tissue Tech Inc.- A Multicenter Phase 3 Confirmatory Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II). It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone.
- June 2024:- Biocomposites Ltd- A Multi-center, Randomized, Controlled Feasibility Trial of STIMULAN VG and Debridement With an Abbreviated Course of Systemic Antibiotics to Debridement and a Full Course of Systemic Antibiotics for the Treatment of Diabetic Foot Osteomyelitis. The purpose of this trial is to evaluate the safety and between-group effect size of STIMULAN VG compared to SoC treatment in patients with diabetic foot osteomyelitis (DFO).
- In 2023, the total prevalent cases of Diabetic Foot Ulcer in the 7MM were highest in US.
- Among EU4 countries and the UK, the highest number of cases of Diabetic Foot Ulcer were

found to be in Italy in 2023.

- In 2023, gender-specific cases of diabetic foot ulcers (DFU) in the 7MM comprised of 60% males and 40% females.
- In the United States, the severity/chronicity of wound-specific diagnosed cases of DFU were 35% and 65% cases for acute/healed wound and chronic/unhealed wound, respectively, in 2023.
- The leading Diabetic Foot Ulcer Companies such as AmnioX, TissueTech, Helixmith, Oneness Biotech, Rheacell, Ticeba, Lakewood-Amedex, Aurealis Therapeutics, Biotherapy Services, Microbion Corporation, Mallinckrodt, and others.
- Promising Diabetic Foot Ulcer Therapies such as BB-101, ENERGI-F703 GEL, TP-102, TTAX01, and others.

Gain a strategic edge with DelveInsight's in-depth analysis of the Diabetic Foot Ulcer Market, including precise Market Size projections and rigorous Market Forecast assessments. Uncover the latest trends in Drugs Market advancements and Treatment Market dynamics to optimize your business decisions effectively @ [Diabetic Foot Ulcer Market Size](#)

Diabetic Foot Ulcer Epidemiology Segmentation in the 7MM

- Total prevalent cases
- Total diagnosed cases
- Gender-specific cases
- Age-specific diagnosed cases,
- Severity/chronicity of wound-specific diagnosed cases
- Treated cases

Explore DelveInsight's authoritative analysis of the Diabetic Foot Ulcer Market, delivering precise forecasts of Market Size and strategic Market Forecast evaluations. Navigate the intricacies of emerging Drugs Market opportunities and evolving Treatment Market dynamics with informed precision @ [Diabetic Foot Ulcer Prevalence](#)

Diabetic Foot Ulcer Marketed Drugs

- Regranex Gel (Becaplermin): Smith & Nephew
Regranex Gel is the first and only FDA-approved recombinant platelet-derived growth factor (PDGF) therapy for diabetic neuropathic ulcers. Regranex Gel, 0.01% contains becaplermin, a human platelet-derived growth factor that is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. Regranex Gel is indicated as an adjunct to, and not a substitute for, good ulcer care practices. Becaplermin containing Regranex is used as a topical administration.

Diabetic Foot Ulcer Emerging Drugs

- TTAX01 (Neox Cord 1K): AmnioX (TissueTech)
Neox Cord 1K combines cryopreserved umbilical cord and amniotic membrane, mirroring the

embryo's inner cell mass with superior processing. TTAX01, utilizing TissueTech's CryoTek technology, preserves the umbilical cord. Amniotic tissue, unique for its regenerative properties, fosters healing with minimal scarring, driven by innate biological factors promoting tissue growth and repair. TTAX01 aims to harness and transplant these properties for therapeutic use beyond the womb. Currently, TTAX01 is in the Phase III.

- Engensis (VM202; Donaperminogene Seltoplasmid): Helixmith
Engensis (VM202) is HelixMith's leading product and is being developed as a plasmid DNA treatment. It produces high levels of HGF protein when administered to muscle. HGF is a protein known to induce various biological responses, such as inducing the formation of new blood vessels, inhibiting fibrosis and inflammation, and promoting nerve regeneration. VM202 is currently in the pivotal Phase III (NCT02563522) stage of development in the US.

Discover DelveInsight's comprehensive coverage of the Diabetic Foot Ulcer Market, offering unparalleled insights into projected Market Size and meticulous Market Forecast predictions. Stay informed on breakthroughs in Drugs Market advancements and Treatment Market strategies to capitalize on future opportunities effectively. @ Diabetic Foot Ulcer Treatment Drug Market Share- https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-dfus-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Foot Ulcer Market Outlook

Key Diabetic Foot Ulcer Companies such as AmnioX (TissueTech), Helixmith, Oneness Biotech and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Diabetic Foot Ulcer (DFU). The high cost of treatment and lack of access to specialists are some of the major factors which might hamper the growth of the market. The launch of TTAX01, Engensis, ON101, ABCB5-positive mesenchymal stem cells, and Bisphosphocin Nu-3, is anticipated during the forecast period. The market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, gene therapy and raised awareness.

Stay ahead in the dynamic Diabetic Foot Ulcer Market landscape. Leverage DelveInsight's expert analysis to understand Market Size trends, predict future Market Forecast, and align your strategies with the shifting dynamics of the Drugs Market and Treatment Market @ Diabetic Foot Ulcer Market Drivers and Barriers- https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-dfus-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Diabetic Foot Ulcer Market Report

- Coverage- 7MM
- Diabetic Foot Ulcer Companies- AmnioX, TissueTech, Helixmith, Oneness Biotech, Rheacell, Ticeba, Lakewood-Amedex, Aurealis Therapeutics, Biotherapy Services, Microbion Corporation, Mallinckrodt, and others.
- Diabetic Foot Ulcer Therapies- BB-101, ENERGI-F703 GEL, TP-102, TTAX01, and others.

- Diabetic Foot Ulcer Market Dynamics: Diabetic Foot Ulcer Market drivers and Diabetic Foot Ulcer Market Barriers
- Diabetic Foot Ulcer Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Diabetic Foot Ulcer Unmet Needs, KOL's views, Analyst's views, Diabetic Foot Ulcer Market Access and Reimbursement

Uncover actionable insights into the Diabetic Foot Ulcer Market dynamics with DelveInsight. From detailed Market Size assessments to precise Market Forecast projections, navigate the complexities of the Drugs Market and Treatment Market with confidence @ Diabetic Foot Ulcer Treatment Market Size- https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-dfus-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Key Insights
2. Executive Summary of Diabetic foot ulcers
3. Competitive Intelligence Analysis for Diabetic foot ulcers
4. Diabetic foot ulcers: Market Overview at a Glance
5. Diabetic foot ulcers: Disease Background and Overview
6. Patient Journey
7. Diabetic foot ulcers Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Diabetic foot ulcers Unmet Needs
10. Key Endpoints of Diabetic foot ulcers Treatment
11. Diabetic foot ulcers Marketed Products
12. Diabetic foot ulcers Emerging Therapies
13. Diabetic foot ulcers: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Diabetic foot ulcers
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients

across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 9650213330
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/725894422>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.